AEON Biopharma, Inc. AEON
AEON Biopharma, Inc. (NYSE: AEON) is a CNS/neurology/psychiatry drug developer. Its lead program, ABP-450, is in Pre-clinical for Botulinum toxin (351(k) biosimilar to Botox; neurology/aesthetic indications). Its next catalyst on record is ABP-450: Written feedback from BPD Type 2b meeting with FDA (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ABP-450 — Written feedback from BPD Type 2b meeting with FDA (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ABP-450 | Botox biosimilar (351(k)) | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.